Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
about
A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomesSBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancerManagement of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Gender Preference in the Sexual Attractions, Fantasies, and Relationships of Voluntarily Castrated MenAdverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.Intermittent androgen deprivation therapy in advanced prostate cancer.Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer.MicroRNA-218 inhibits tumor growth and increases chemosensitivity to CDDP treatment by targeting BCAT1 in prostate cancer.Treatment of Metastatic Prostate Cancer in Older Adults.Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies.The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer.Differential effect of estradiol and bisphenol A on Set8 and Sirt1 expression in prostate cancer.The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.Prostate cancer and the increasing role of active surveillance.Long-term impact of androgen-deprivation therapy on physical function and quality of life.Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017.Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.Stereotactic ablative body radiotherapy in patients with prostate cancer
P2860
Q30780322-9F67FED8-7B4F-4156-B082-F4B263CDBB80Q33890406-5ED4509F-42F9-4627-80A9-D2FBFDB6C543Q35569482-A19EE0BE-9542-4734-AC0B-53EB7DFBEC87Q35789050-1191C8AE-A86A-447E-ACA0-1D5BF3E023C0Q35879087-AB474F85-DD9C-468F-AA17-7ABA31AC92F6Q36770068-69968027-4A78-480B-B267-3EA796A16EECQ36854835-EAF3C96A-2720-4A3D-B19C-42A93FD015D5Q37554029-07C6E98B-E2DF-4808-8BA9-C943D6F4F2BEQ37592301-237E822A-E9EF-4FE1-8085-0763994D5FA3Q38176254-9F377CB9-1BC1-4B10-AEE9-A1E9FF4FBE4DQ38179060-11E1FFCF-74C6-40C3-98D4-71D816AB4016Q38200898-5DC945BF-D5E8-4C84-B651-168DCEC48EEBQ38353806-6A589E2D-DB8D-4C4C-8151-A471E280D74DQ38774889-E4CDCF13-927F-4278-8503-58F890D8201EQ38944255-6BD1EACA-5215-436A-83CD-6D64106D8812Q38957279-BFCDAD0A-F971-4B1C-9CDF-7586F84E6711Q39041932-95F7A7BC-A14B-4FBB-A2D9-906453F7A2D6Q41188480-35DD8E45-4A7E-48DE-B0C7-EB00FCF3A33DQ41680469-2134AD89-8F69-4B6B-9DCB-FB21F7E4092DQ45408608-70B90CA2-A1D9-4BDE-952B-4B9C146F434EQ46054276-49F1D8A3-087E-46F6-892C-4BBEED520C37Q48044119-068EA9DC-1326-4B00-BDDA-3E77545A3280Q48081685-FE806371-E210-4612-A3D2-3A96D2050D31Q52563735-39B7AF19-36C4-4AD9-B7DF-D24AD036A349Q54917990-C938F532-68A6-43AC-B9A0-9BC584743E71Q55024078-0B62EA5D-08F6-41FE-BFF3-2AE70098FA1BQ55194983-D03305D5-2C82-4012-8233-E4CE6CF1E3B0Q57112486-1CC1482B-1FB6-44B2-97CD-A450512F519B
P2860
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Treatment of prostate cancer w ...... c review of randomized trials.
@ast
Treatment of prostate cancer w ...... c review of randomized trials.
@en
Treatment of prostate cancer w ...... c review of randomized trials.
@nl
type
label
Treatment of prostate cancer w ...... c review of randomized trials.
@ast
Treatment of prostate cancer w ...... c review of randomized trials.
@en
Treatment of prostate cancer w ...... c review of randomized trials.
@nl
prefLabel
Treatment of prostate cancer w ...... c review of randomized trials.
@ast
Treatment of prostate cancer w ...... c review of randomized trials.
@en
Treatment of prostate cancer w ...... c review of randomized trials.
@nl
P356
P1476
Treatment of prostate cancer w ...... ic review of randomized trials
@en
P2093
Ian F Tannock
P304
P356
10.1200/JCO.2012.46.5492
P407
P577
2013-04-29T00:00:00Z